Cellectar Biosciences (NV40) Financial Statements
Cellectar Biosciences Financial Overview
Cellectar Biosciences's market cap is currently $10.20M. The company's EPS TTM is $-4.56; its P/E ratio is -0.26; Cellectar Biosciences has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -213.60K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -22.98M | $ -51.78M | $ -38.96M | $ -28.81M | $ -24.13M |
| EBITDA | $ -21.58M | $ -44.22M | $ -42.64M | $ -31.70M | $ -23.97M |
| Net Income | $ -21.79M | $ -44.58M | $ -42.77M | $ -31.79M | $ -24.12M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 13.20M | $ 23.29M | $ 9.56M | $ 19.87M | $ 35.70M |
| Total Assets | $ 14.98M | $ 25.47M | $ 12.08M | $ 21.59M | $ 37.20M |
| Total Debt | $ 409.59K | $ 494.00K | $ 552.98K | $ 603.83K | $ 301.74K |
| Net Debt | $ -12.79M | $ -22.79M | $ -9.01M | $ -19.26M | $ -35.40M |
| Total Liabilities | $ 5.06M | $ 11.18M | $ 25.85M | $ 12.05M | $ 4.16M |
| Stockholders' Equity | $ 9.92M | $ 14.29M | $ -13.78M | $ 9.54M | $ 33.05M |
| Cash Flow | |||||
| Free Cash Flow | $ -23.12M | $ -47.69M | $ -33.24M | $ -25.45M | $ -22.71M |
| Operating Cash Flow | $ -23.12M | $ -47.58M | $ -32.38M | $ -25.22M | $ -22.57M |
| Investing Cash Flow | $ -5.88K | $ -104.19K | $ -864.04K | $ -225.97K | $ -141.36K |
| Financing Cash Flow | $ 13.03M | $ 61.41M | $ 22.94M | $ 9.61M | $ 1.25M |
Currency in USD
